DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

A Canadian woman with stage 4 cancer says she ignored signs of the disease because she believed them to be “eczema-related.” ...

A woman who thought she had eczema has been diagnosed with stage 4 cancer. Taylor Deanne Roy started getting itchy skin in ...

A 32-year-old woman who has been diagnosed with stage 4 cancer says she ignored early signs because she thought they were ...

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular ... in Europe are diagnosed with ...

Taylor Deanne Roy, 32, had noticed a series of symptoms over a two-year period, but didn't think they were anything to be too ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

FOR years, Taylor Deanne Roy dismissed her shortness of breath and itchy skin as signs she was simply “getting older”. So ...